Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inclusion of "pharmacist" on OTC label warnings supported by majority of cmte. members.

This article was originally published in The Tan Sheet

Executive Summary

"PHARMACIST" INCLUSION IN OTC LABEL WARNINGS endorsed by a majority of the members of FDA's Nonprescription Drugs Advisory Committee at a July 14 meeting in Bethesda, Md. Asked by the agency to discuss possible alternatives to the "Ask a Doctor Before Use" phrase suggested in FDA's proposed rule on OTC label reform, the committee members recommended a number of possible options, with "pharmacist" and "health care professional" receiving the most support. The group did not vote on the issue; NDAC Chairman Ralph D'Agostino, PhD, Boston University, instead polled individual members for their preferences.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel